Conferences
ASCO GU 2024: Advanced Urothelial Carcinoma Discussant
January 29, 2024
ASCO GU 2024: Keynote Lecture - Charting New Paths: Increasing Patient Representation in Genitourinary Malignancy Trials
January 29, 2024
ASCO GU 2024: A New Era in the Perioperative Management of Muscle Invasive Bladder Cancer
January 29, 2024
ASCO GU 2024: Drug Sequencing, Pairing, Switching, and the Role of Checkpoint Re-Challenging
January 29, 2024
ASCO GU 2024: Drug Shortages: Why Are They a Recurrent Issue and What Can Regulatory Do to Prevent Them?
January 29, 2024
ASCO GU 2024: Lessons Learned: What Can Other Disease Sites Teach Us About Practical Implications of Checkpoint Therapy in Urothelial Carcinoma?
January 29, 2024
ASCO GU 2024: Surgical Therapeutic Role for Node-Positive Disease: Does It Make a Difference?
January 29, 2024
ASCO GU 2024: Genetic Testing in RCC: Who, When, and How?
January 29, 2024
ASCO GU 2024: Management of Non-Clear Cell Renal Cell Carcinoma
January 29, 2024
ASCO GU 2024: Harnessing the Power: Biologic Basis of Pairing and Sequencing Checkpoints with Other Therapy
January 28, 2024
ASCO GU 2024: Association Between SPECT/CT Total Tumor Volume and New Lesions in Early Cycles of 177Lu-PSMA-617 and PFS and OS in Men with mCRPC
January 28, 2024
ASCO GU 2024: Neoadjuvant Combined Chemotherapy and Immunotherapy for Upper Tract Urothelial Carcinoma: Preliminary Results From a Phase II Study
January 28, 2024